hydroxychloroquine has been researched along with Acute Rheumatic Fever in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In-vitro evidence suggests hydroxychloroquine could be a potential immunomodulator for the inflammatory carditis of acute rheumatic fever (ARF)." | 8.12 | Revisiting QT prolongation in acute rheumatic fever - Relevance for hydroxychloroquine treatment. ( Agnew, J; Han, DY; Nicholson, R; Perelini, F; Skinner, JR; Wilson, N, 2022) |
| "Hydroxychloroquine (HCQ) suppresses an interleukin-1β-granulocyte-macrophage colony-stimulating factor cytokine axis, reported to be dysregulated in peripheral blood mononuclear cells of acute rheumatic fever patients ex vivo." | 7.96 | The Treatment of Acute Rheumatic Fever: Novel Use of Hydroxychloroquine. ( Concannon, A; Davidakova, S; Malcolm, J; Martin, WJ; Moreland, NJ; Webb, R; Wilson, NJ, 2020) |
| "Acute rheumatic fever (ARF) and rheumatic heart disease are autoimmune consequences of group A streptococcus infection and remain major causes of cardiovascular morbidity and mortality around the world." | 5.48 | Dysregulated IL-1β-GM-CSF Axis in Acute Rheumatic Fever That Is Limited by Hydroxychloroquine. ( Carapetis, J; Garnham, AL; Keeble, JL; Kim, ML; Martin, WJ; Minigo, G; Pacini, G; Smyth, GK; Speed, TP; Wicks, IP, 2018) |
| "In-vitro evidence suggests hydroxychloroquine could be a potential immunomodulator for the inflammatory carditis of acute rheumatic fever (ARF)." | 4.12 | Revisiting QT prolongation in acute rheumatic fever - Relevance for hydroxychloroquine treatment. ( Agnew, J; Han, DY; Nicholson, R; Perelini, F; Skinner, JR; Wilson, N, 2022) |
| "Hydroxychloroquine (HCQ) suppresses an interleukin-1β-granulocyte-macrophage colony-stimulating factor cytokine axis, reported to be dysregulated in peripheral blood mononuclear cells of acute rheumatic fever patients ex vivo." | 3.96 | The Treatment of Acute Rheumatic Fever: Novel Use of Hydroxychloroquine. ( Concannon, A; Davidakova, S; Malcolm, J; Martin, WJ; Moreland, NJ; Webb, R; Wilson, NJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Perelini, F | 1 |
| Agnew, J | 1 |
| Skinner, JR | 1 |
| Han, DY | 1 |
| Nicholson, R | 1 |
| Wilson, N | 1 |
| Zheng, YQ | 1 |
| Li, HJ | 1 |
| Chen, L | 1 |
| Lin, SP | 1 |
| Wilson, NJ | 1 |
| Concannon, A | 1 |
| Malcolm, J | 1 |
| Davidakova, S | 1 |
| Martin, WJ | 2 |
| Webb, R | 1 |
| Moreland, NJ | 1 |
| Sheha, D | 1 |
| El-Shayeb, M | 1 |
| Eid, Y | 1 |
| Amin, M | 1 |
| Saeed, A | 1 |
| Abdou, D | 1 |
| Aly, T | 1 |
| Samy, S | 1 |
| Elziaty, R | 1 |
| Aboelyazed, S | 1 |
| Osman, A | 1 |
| Sheha, A | 1 |
| Kim, ML | 1 |
| Minigo, G | 1 |
| Keeble, JL | 1 |
| Garnham, AL | 1 |
| Pacini, G | 1 |
| Smyth, GK | 1 |
| Speed, TP | 1 |
| Carapetis, J | 1 |
| Wicks, IP | 1 |
| Kuriakose, T | 1 |
| Kanneganti, TD | 1 |
| KERUZORE, A | 1 |
| COSTE, F | 1 |
| DELBARRE, F | 1 |
7 other studies available for hydroxychloroquine and Acute Rheumatic Fever
| Article | Year |
|---|---|
Revisiting QT prolongation in acute rheumatic fever - Relevance for hydroxychloroquine treatment.
Topics: Child; COVID-19 Drug Treatment; Electrocardiography; Humans; Hydroxychloroquine; Long QT Syndrome; P | 2022 |
Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases.
Topics: Antibodies, Viral; Autoimmune Diseases; COVID-19; COVID-19 Vaccines; Humans; Hydroxychloroquine; Imm | 2022 |
The Treatment of Acute Rheumatic Fever: Novel Use of Hydroxychloroquine.
Topics: Adolescent; Antirheumatic Agents; Biomarkers; Child; Humans; Hydroxychloroquine; Inflammation; Inter | 2020 |
Unfolding of sickle cell trait by coronavirus disease 2019 (COVID-19) infection.
Topics: Adrenal Cortex Hormones; Anticoagulants; Azithromycin; Combined Modality Therapy; COVID-19; COVID-19 | 2020 |
Dysregulated IL-1β-GM-CSF Axis in Acute Rheumatic Fever That Is Limited by Hydroxychloroquine.
Topics: Adolescent; Adult; C-Reactive Protein; CD4-Positive T-Lymphocytes; Cell Differentiation; Child; Cyto | 2018 |
Is Inflammasome a Potential Target of Prophylaxis in Rheumatic Heart Disease?
Topics: Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydroxychloroquine; Inflammasomes; Interle | 2018 |
[The treatment of inflammatory rheumatism by antimalarials (chloroquine and hydroxychloroquine)].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Rheumatic Diseases; Rheumatic Fever | 1960 |